MSFrontier

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

Exploring the Utility of [18F]3F4AP for Demyelination Imaging
RecruitingPhase 1MS (type not specified)NCT06999434

What it found

Still running

No result yet.

What was tested

Treatment tested

  • [ 18F]3F4AP
  • [18F]MK6240
  • [11C]PIB

What it measured

Main measures

  • Tracers volume of distribution (VT)

    5 years

  • Distribution volume ratio (DVR)

    5 years

  • Binding potential (BPND)

    5 years

  • Demyelination

    5 years

    MRI lesions

  • Tau burden

    5 years

  • Amyloid burden

    5 years

  • Tracer rate constant

    5 years

  • Associations between imaging modalities and biomarkers.

    5 years

    Blood or spinal fluid markersPhysical function

Other measures (4)

  • Measure of brain atrophy

    5 years

    MRI lesionsBrain volume loss

  • Measure of cerebrovascular burden

    5 years

    MRI lesions

  • Measure of White matter lesions (WML)

    5 years

    MRI lesions

  • MR/MRSI images

    5 years

Who could take part

MS (type not specified) · 18 to 90

Inclusion: 1. Male and Female subjects must be ≥18 and \<90 years of age; 2. Able to understand and provide informed consent prior to study procedures 3. Must be in good health Exclusion: 1. Less than 18 years of age; 2. Pregnant or breastfeeding; 3. Any significant systemic illness or unstable medical condition; 4. Pre-existing medical conditions or claustrophobic reactions; 5. Research-related radiation exposure exceeds current PET Center guidelines (i.e. 50 mSv in the prior 12 months); 6. History of a bleeding disorder or are currently taking anticoagulants.

As registered. Criteria can change, so ask the trial team or your neurologist.

Contact details on the registry

About this trial

In the sponsor's words

The overall objective is to obtain an assessment of the pharmacokinetics of [18F]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).

Loading reviews and guidelines…

Related trials

History

    1. Started

      May 2025

    2. Main results due

      May 2030

    3. Finished

      May 2030

    Assembled by software from public sources and not checked by people. Each record links to its source. Report an error